Clinical Trial Update: A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. [Phase 1]

View source ↗

Summary

Phase 1 clinical trial to assess the pharmacokinetic interactions of multiple doses of rezatapopt with metformin, rosuvastatin, repaglinide, and midazolam in pa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Midazolam (Midazolam)
• Repaglinide (Repaglinide)
• Rezatapopt (rezatapopt)
• Rosuvastatin (rosuvastatin)
• metformin (metformin)

Snippet

Sponsor: PMV Pharmaceuticals, Inc | Conditions: TP53 Y220C Mutation, Advanced Solid Tumors | Phase 1 | Status: RECRUITING